EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Prophylactic Efficacy of CD388, a Novel Drug–Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study

Roxana E Rojas, Ozlem Equils, Jorge Villacian, Alex Mann, Wilbert van Duijnhoven iD, Johan Vingerhoets, Tristan Baguet iD, Sy-Shi Wang, Arun Anandakumar, Antoinette Anger, Alice Tourneroche, Isabel Gonçalves Silva und 1 weitere

Clinical Infectious Diseases · 24.12.2025 · 81 (5) · e310-e318

DOI: 10.1093/cid/ciaf465 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 08.10.2025. Verfasst von Roxana E Rojas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Communicable Diseases, Johnson & Johnson, Brisbane, California, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Immunoglobulin Fc Fragments, Influenza A Virus, H3N2 Subtype, Influenza, Human. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Pharmaceuticals, Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Influenza is a significant public health concern, especially in immunocompromised patients. CD388 is a novel multivalent zanamivir conjugate that is stably linked to a proprietary human immunoglobulin G1 Fc with a long half-life for prevention of influenza. Here we report a proof-of-concept study on the prophylactic activity of subcutaneously administered CD388 against influenza challenge.

Methods

In a randomized, double-blind, placebo-controlled, phase 2a human challenge study, a single dose of CD388 (50 or 150 mg) was subcutaneously administered in healthy participants 5 days before intranasal challenge with influenza A (H3N2). Safety, pharmacokinetics, infection rate (by reverse transcription–quantitative polymerase chain reaction methods [RT-qPCR]), intranasal viral load (VL), and symptoms were compared between the CD388 and placebo treatment groups.

Results

The area under the VL–time curve (VL-AUC), primary endpoint, was lower in the CD388 150 mg group (n = 28) compared with the placebo group (n = 28; mean 10.70 log10 [copies/mL] × days vs mean 16.09 log10 [copies/mL] × days; P = .0390). Peak VL and the rate of RT-qPCR–confirmed influenza infection were lower in the CD388 group versus the placebo group (P = .0185 and P = .0248, respectively). Clinical symptom scores were numerically lower among participants treated with CD388 compared with participants treated with placebo. There were a limited number of treatment-emergent adverse events. Anti-drug antibody development was rare and not clinically relevant.

Conclusions

CD388 was well-tolerated and demonstrated prophylactic activity against RT-qPCR–confirmed influenza infection in a human challenge study. The efficacy of CD388 in preventing influenza will be confirmed in larger studies. Clinical Trials Registration. ClinicalTrials.gov identifier: NCT05523089.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsImmunoglobulin Fc FragmentsInfluenza A Virus, H3N2 SubtypeInfluenza, HumanZanamivirAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodViral Load

Stichwörter der Autor:innen

drug–Fc conjugatehuman challenge model (HCM) (minimum 1influenzamaximum 5)

Substanzen

Antiviral AgentsImmunoglobulin Fc FragmentsZanamivir

Autor:innen und Institutionen

  • Communicable Diseases, Johnson & Johnson, Brisbane, California, USA.
  • Cidara Therapeutics, San Diego, California, USA.
  • Infectious Diseaes Research & Development, Johnson & Johnson, Beerse, Belgium.
  • hVIVO, London, United Kingdom.
  • Venn Life Sciences, Paris, France.

ORCID-Profile: Wilbert van Duijnhoven, Tristan Baguet, Shawn Flanagan

Förderung

  • Janssen Pharmaceuticals
  • Johnson & Johnson

Zitieren

APA

Rojas, R. E., Equils, O., Villacian, J., Mann, A., van Duijnhoven, W., Vingerhoets, J., Baguet, T., Wang, S. S., Anandakumar, A., Anger, A., Tourneroche, A., Silva, I. G., & Flanagan, S. (2025). Prophylactic Efficacy of CD388, a Novel Drug–Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study. Clinical Infectious Diseases, 81(5), e310-e318. https://doi.org/10.1093/cid/ciaf465

Vancouver

Rojas RE, Equils O, Villacian J, Mann A, van Duijnhoven W, Vingerhoets J, et al. Prophylactic Efficacy of CD388, a Novel Drug–Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study. Clinical Infectious Diseases. 2025;81(5):e310-e318. doi:10.1093/cid/ciaf465

BibTeX
@article{Rojas2025,
  author = {Rojas, Roxana E and Equils, Ozlem and Villacian, Jorge and Mann, Alex and van Duijnhoven, Wilbert and Vingerhoets, Johan and Baguet, Tristan and Wang, Sy-Shi and Anandakumar, Arun and Anger, Antoinette and Tourneroche, Alice and Silva, Isabel Gonçalves and Flanagan, Shawn},
  title = {Prophylactic Efficacy of CD388, a Novel Drug–Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {5},
  pages = {e310--e318},
  doi = {10.1093/cid/ciaf465}
}
Kostenlos starten →